You are here: Industry Insights > Eli Lilly

News List

Lilly launches Phase I trial of investigational COVID-19 antibody treatment europeanpharmaceuticalreview
June 05, 2020
The enterprise announced the initiation of the LY-CoV555 COVID-19 antibody treatment trial at medical centres across the US.
Lilly, AbCellera Dose First Patients with COVID-19 Antibody contractpharma
June 02, 2020
Phase 1 study of LY-CoV555 is the world's first study of a potential antibody treatment designed to fight COVID-19.
Lilly Receives FDA Approval for Treatment of RET-Driven Lung and Thyroid Cancers americanpharmaceuticalreview
May 14, 2020
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg capsules).
Lilly receives US FDA approval for Retevmo pharmaceutical-business-review
May 13, 2020
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) approved Retevmo (selpercatinib, 40 mg & 80 mg capsules).
Junshi, Lilly to Co-develop Antibody Therapies for COVID-19 contractpharma
May 13, 2020
Multiple neutralizing antibodies have been engineered, with the lead asset poised to enter clinical testing in the second quarter.
Lilly secures FDA approval for Retevmo to treat lung/thyroid cancers pharmaceutical-technology
May 12, 2020
Eli Lilly has secured accelerated approval from the US Food and Drug Administration (FDA) for the use of Retevmo (selpercatinib) to treat lung and thyroid cancers.
Eli Lilly, Junshi collaborate to develop antibody therapies for Covid-19 disease pharmaceutical-business-review
May 05, 2020
Eli Lilly has collaborated with Junshi Biosciences for the development of therapeutic antibodies to treat and prevent Covid-19, the disease resulted due to the SARS-CoV-2 novel coronavirus.
Eli Lilly’s COVID-19 therapies to enter clinical trials europeanpharmaceuticalreview
April 17, 2020
The enterprise announced its drug OLUMIANT® (baricitinib) and an investigational antibody will enter clinical trials in US COVID-19 patients later this month.
Lilly Begins Clinical Testing of Therapies for COVID-19 americanpharmaceuticalreview
April 15, 2020
Eli Lilly and Company has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Lilly, NIAID to Study Baricitinib in COVID-19 contractpharma
April 14, 2020
Baricitinib's anti-inflammatory activity has been hypothesized to have a potential benefit in COVID-19.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page